| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.4 | 9.4 |
| Gross profit | 3.1 | 3.1 |
| Profit before tax | -1.3 | -1.0 |
| Net income | -1.2 | -0.9 |
| EPS (diluted, $ a share) | $-5.20 | $-38.80 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +0.3% |
|---|---|
| Gross margin | 32.8% |
| Operating margin | -13.7% |
10-Q filed with the SEC, NASDAQ: SBFM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sunshine Biopharma Inc.: key numbers
- Share price
- $2.60Close, Nov 16
- Market cap
- $2.14M
- Shares outstanding
- 823.77KLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sunshine Biopharma Inc.
All →Sunshine Biopharma Shareholder Meeting
The majority shareholder and CEO, Dr. Steve N. Slilaty, approved by written consent several matters related to a public offering that closed on October 9, 2026. These approvals include the issuance of common stock in excess of 20% of outstanding shares at a discount and adjustments to the exercise price and share count of Series D Warrants.
Sunshine Biopharma Capital Raise of $6M
Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.
- Value
- $6M
- Counterparty
- Aegis Capital Corp.
Sunshine Biopharma Reverse Stock Split
Sunshine Biopharma's majority shareholder, CEO Dr. Steve N. Slilaty, has approved a written consent authorizing the board to effect a reverse stock split at a ratio of up to 1-for-20. The board retains discretion over the final ratio and the timing of the split, which will become effective 20 days after a definitive information statement is mailed to stockholders.
Sunshine Biopharma Other 8-K Filing
Sunshine Biopharma announced a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. This adjustment was triggered by recent sales of common stock under the company's existing at-the-market (ATM) offering program. The price remains subject to further potential adjustments based on the terms of the warrants.